Physician profile
Spring M Peavy
NPI 1871805127
$3,917.89
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $1,235 · 2023: $631 · 2024: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $888.38 | 2021-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $449.90 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $371.77 | 2021-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.06 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $331.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $218.28 | 2021-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $207.43 | 2021-2023 | Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $165.25 | 2021 | |
| Glaxosmithkline, LLC. | $149.14 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $92.84 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $77.85 | 2021-2023 | |
| Pfizer INC. | $76.81 | 2021 | |
| Amarin Pharma, INC. | $71.82 | 2021-2022 | |
| Exact Sciences Corporation | $57.00 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $56.92 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.40 | 2022-2023 | Xifaxan |
| Edwards Lifesciences Corporation | $33.41 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Horizon Therapeutics Plc | $21.67 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $21.29 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $21.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.24 | 2022 | |
| Axsome Therapeutics, INC. | $21.22 | 2022 | |
| Abbott Laboratories | $20.92 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.70 | 2021 | |
| Astellas Pharma US INC | $17.50 | 2021 | |
| Phadia US INC. | $17.06 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.17 | 2022 | |
| Halozyme INC | $15.99 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.94 | 2022 | |
| Medicure Pharma INC. | $13.92 | 2023 | Zypitamag |
| Eisai INC. | $13.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.69 | 2021 | |
| Clarus Therapeutics INC. | $8.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spring Peavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.